Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer

Zhang, Yi; Cao, Junyan; Deng, Yihui; Huang, Yiming; Li, Rong; Lin, Guozhen; Dong, Min; Huang, Zenan

doi:10.6061/clinics/2020/e993

Cited by 28 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These values were significantly higher in patients with poor outcomes. Our results are in accordance with other studies that have confirmed the prognostic potential of fibrinogen in many types of malignancy [26][27][28]. Similar findings were reported in laryngeal, nasopharyngeal, oral, and oropharyngeal squamous cell carcinomas, where elevated preoperative levels of fibrinogen were associated with worse outcomes and resistance to therapy [29][30][31].…”

Section: Discussionsupporting

confidence: 92%

The Hidden Treasures of Preoperative Blood Assessment in Oral Cancer: A Potential Source of Biomarkers

Căruntu

Moraru

Lupu

et al. 2021

Cancers

View full text Add to dashboard Cite

(1) Background: Oral squamous cell carcinoma (OSCC) is a common malignancy, and the impact of immune and inflammatory mechanisms in its development and progression are of major interest. The aim of our study is to assess the prognostic potential of circulating immune and inflammatory elements determined preoperatively in patients with OSCC, as well as the development of a new compound parameter with predictive value. (2) Methods: We assessed preoperative fibrinogen (Fib) and the platelet-to-lymphocyte ratio (PLR) in 111 OSCC patients. Using a mathematic algorithm, we determined a composite parameter with cumulative information from Fib and PLR, named Fibrinogen-PLR Algorithm (FiPLA). Survival analysis, followed by bivariate and multivariate analyses, was subsequently conducted. (3) Results: Increased preoperative Fib and PLR levels were associated with poor outcome in OSCC (p = 0.0001 and p = 0.0015, respectively). Preoperative FiPLA values were also associated with poor patient survival (p < 0.0001). Multivariate analysis confirmed the independent prognostic role for FiPLA only (CI95% 1.232–67.770, p = 0.03), showing the superior predictive value of FiPLA compared to its individual components. (4) Conclusions: Preoperative assessments of circulating immune and inflammatory elements can provide high-quality prognostic information, and they represent valuable tools in clinical practice, facilitating the early risk stratification of patients with OSCC.

show abstract

Section: Discussionsupporting

confidence: 92%

The Hidden Treasures of Preoperative Blood Assessment in Oral Cancer: A Potential Source of Biomarkers

Căruntu

Moraru

Lupu

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…29 , 30 Elevated FIB concentration indicates activation of the hemostasis and fibrinolysis system, which promotes tumor angiogenesis, metastasis, and invasion. 31 , 32 We found that patients with advanced NSCLC tended to have lower LY % and higher FIB, which was consistent with the results reported by Iseki et al 33 and Zhang et al 34 Therefore, LY %, FIB, and FLR were significantly associated with tumor staging, which was mentioned in some previous studies. 27 , 34 , 35 However, the research conducted by Li et al 36 showed that there was no statistical difference in the concentration of FIB between different tumor stages, which might be due to the large differences in the number of patients with early, middle, and advanced disease in the selected patients.…”

Section: Discussionsupporting

confidence: 89%

Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy

Liu¹,

Yang²,

Wan³

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose The objective of our study was to assess the association between lymphocyte percentage (LY%), fibrinogen (FIB), fibrinogen-to-lymphocyte percentage ratio (FLR) and the tumor staging and the clinical outcome role in non-small cell lung cancer (NSCLC) patients with chemotherapy or surgery combined with chemotherapy. Patients and Methods Between August 2013 and October 2020, 375 patients initially diagnosed with NSCLC and 201 healthy subjects were enrolled in the retrospective study. The concentrations of LY%, FIB, and FLR were compared between the case group and the control group by using the Mann–Whitney U -test or Kruskal–Wallis test, and then these biomarkers were compared in terms of the tumor category and PTNM stage of the test group, etc. The cutoffs of LY%, FIB, and FLR were determined using X-tile software. The prognostic roles of LY%, FIB, and FLR were identified by the Kaplan–Meier curve and Cox regression model. The biological markers on overall survival (OS) were analyzed. Results The study showed that the concentration levels of LY%, FIB, and FLR in the stage III–IV group were significant difference from those in the stage I–II group (P<0.001), indicating that three biomarkers (LY%, FIB, and FLR) were significantly correlated with tumor staging. Pretreatment high FIB and FLR and low LY% indicated an increased risk of death in NSCLC patients. Also, it was found that the clinical outcome of low FLR patients with chemotherapy or chemotherapy combined with surgery was superior to high FLR patients. Conclusion Our findings demonstrated that FLR could be used to predict NSCLC staging and was an independent prognosis factor within NSCLC patients receiving chemotherapy or chemotherapy combined with surgery.

show abstract

“…Fibrinogen as biomarker has been investigated for several diseases including chronic obstructive pulmonary disease and coronary heart disease [161,162]. Additionally, a negative prognostic value of high pretreatment fibrinogen has been found for numerous tumor entities [98,114,[163][164][165][166][167]. So far, only the previous study of the authors reported not only a prognostic but also predictive value for pretreatment fibrinogen in MPM.…”

Section: Fibrinogenmentioning

confidence: 99%

Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation

Vogl

Rosenmayr

Bohanes

et al. 2021

Cancers

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment response and devastating prognosis. Exposure to asbestos and chronic inflammation are acknowledged as main risk factors. Since immune therapy evolved as a promising novel treatment modality, we want to reevaluate and summarize the role of the inflammatory system in MPM. This review focuses on local tumor associated inflammation on the one hand and systemic inflammatory markers, and their impact on MPM outcome, on the other hand. Identification of new biomarkers helps to select optimal patient tailored therapy, avoid ineffective treatment with its related side effects and consequently improves patient’s outcome in this rare disease. Additionally, a better understanding of the tumor promoting and tumor suppressing inflammatory processes, influencing MPM pathogenesis and progression, might also reveal possible new targets for MPM treatment. After reviewing the currently available literature and according to our own research, it is concluded that the suppression of the specific immune system and the activation of its innate counterpart are crucial drivers of MPM aggressiveness translating to poor patient outcome.

show abstract

Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer

Cited by 28 publications

References 31 publications

The Hidden Treasures of Preoperative Blood Assessment in Oral Cancer: A Potential Source of Biomarkers

The Hidden Treasures of Preoperative Blood Assessment in Oral Cancer: A Potential Source of Biomarkers

Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy

Biomarkers for Malignant Pleural Mesothelioma—A Novel View on Inflammation

Contact Info

Product

Resources

About